Search papers, labs, and topics across Lattice.
LUCAID is an advanced AI system designed for precision pathology in lung cancer, integrating multiple diagnostic modules to enhance the accuracy of tissue diagnostics. By addressing the limitations of existing AI tools, which often lack comprehensive validation and struggle with interobserver variability, LUCAID achieved an impressive 93.0% concordance with expert decisions in prospective clinical validation. The system's modular approach allows for interactive querying and structured report generation, significantly improving diagnostic workflows and decision-making in oncology.
LUCAID outperforms experienced pathologists by achieving 93% concordance in lung cancer diagnostics, setting a new standard for AI in precision oncology.
Lung cancer tissue diagnostics is complex, as therapy decisions in precision oncology rely on the integration of histomorphological, immunohistochemical, and molecular features. Yet pathological assessment remains largely visual and semi-quantitative and shows interobserver variability, while existing artificial intelligence (AI) tools cover only selected tasks, rarely reach generalizable expert-level performance, and lack prospective clinical validation. To address these challenges, we developed and clinically validated LUCAID, an agentic AI system for precision lung cancer pathology. An integrative agent couples diagnostic reasoning with nine modules that cover the full routine workflow, from quality control, tumor detection and segmentation, histological subtyping, tumor microenvironment profiling, tumor cellularity quantification, and predictive biomarker scoring (PD-L1, MET, TROP-2) to automated structured report generation. LUCAID enables users to interactively query the module outputs and generate reports that contextualize the results. Against large-scale expert ground-truth annotations, the analysis modules achieved F1 scores of 0.82-0.95. In prospective clinical validation, LUCAID reached 93.0% concordance with an expert-panel adjudicated reference standard across clinically actionable decisions, compared with 68.3-81.1% for five experienced thoracic pathologists.
